secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168448
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.78
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus to acquire Surface Oncology for upfront stock worth ~$40M+ net cash plus CVRs
--------------------------------------------------------------------------------

- Upfront consideration: Coherus stock valued using $5.2831/share based on $40M plus Surface's net cash (min $19.6M).
- Each Surface share also receives one CVR for 70% of milestones/royalties from GSK and Novartis partnerships.
- CVRs also include 25% of upfront payments for SRF114 and 50% for SRF388 out-licensing, less development costs.
- Closing conditions: Surface stockholder approval, net cash ≥$19.6M, S-4 effectiveness, and no material adverse effect.
- Termination fee of ~$2M payable by Surface if it accepts a superior proposal or breaches non-solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/0001193125-23-168448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/d523169d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer